Objective To explore serum levels of fibroblast growth factor-23 (FGF-23) and soluble growth stimulation expressed gene 2 (sST2) in the prediction of heart valve calcification in elderly patients with end-stage renal disease (ESRD) on hemodialysis. Methods A total of 106 elderly ESRD patients on hemodialysis admitted to the Seventh Affiliated Hospital of Xinjiang Medical University from June 2018 to June 2021 were recruited as the observation group, and a total of 106 healthy individuals for physical check-up were recruited as the control group. Serum FGF-23 and sST2 levels were compared between the two groups. The observation group was followed up until January 2022, and the incidence of heart valve calcification in this group was then calculated. The influencing factors for heart valve calcification and the interaction of FGF-23 and sST2 in the pathogenesis of heart valve calcification were analyzed. The values of FGF-23 and sST2 in predicting heart valve calcification were then evaluated. Results Serum FGF-23 and sST2 levels were higher in the observation group than in the control group (t=35.539 and 45.748, P＜0.001). Higher expressions of FGF-23 and sST2 increased the risk of heart valve calcification (OR=4.539 and 4.265, 95% CI：2.527~8.154 and 2.008~9.057, P＜0.001). After adjusting for confounding factors, there was a positive interaction between FGF-23 and sST2 on the occurrence of cardiac valve calcification. The synergistic effect was 2.631 times higher than the sum of the effects of the two individually (SI=2.631). The area under the curve (AUC) of combined FGF-23 and sST2 was greater than that of FGF-23 or sST2 for the prediction of heart valve calcification (AUC=0.851, 95% CI：0.767~0.913, P＜0.001). Conclusion Serum FGF-23 and sST2 levels abnormally increased in elderly ESRD patients on hemodialysis. The effects of FGF-23 and sST2 were synergistic in the pathogenesis of heart valve calcification, and combination of the two can efficiently improve the prediction of heart valve calcification.
WANG Wei
. Changes of serum FGF-23 and sST2 levels and their predictive value for cardiac valve calcification in elderly patients with end-stage renal disease on hemodialysis[J]. Chinese Journal of Blood Purification, 2023
, 22(02)
: 100
-104
.
DOI: 10.3969/j.issn.1671-4091.2023.02.005
1 Zhao Z,Qiao H,Ge Y,et al.Autoimmune experimental orchitis and chronic glomerulonephritis with end stage renal disease are controlled by Cgnz1 for susceptibility to end organ damage[J].Clin Immunol,2021,224(1):108675.
2 Miao J,Sy-Go JPT,Issa M,et al.Ultrasonographic Assessment of Extravascular Lung Water in Hospitalized Patients Requiring Hemodialysis: A Prospective Observational Study[J].Cardiorenal Med,2021,11(3):151-160.
3 Medicherla RC,Phair J,Carnevale M,et al.Cardiac valve replacement for infective endocarditis in patients with end stage renal disease on hemodialysis - A single institution experience[J].Vascular,2020,28(1):104-108.
4 van der Wal HH,Beverborg NG,Ter Maaten JM,et al.Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure[J].Eur J Heart Fail,2020,22(5):903-906.
5 孔祥权,王志梅,高晓飞,等.急性心肌梗死后血浆可溶性生长刺激表达基因2蛋白与左心室重构的关系[J].心脏杂志,2019,31(4):414-416,421.
6 Zhang Y,Fan Z,Liu H,et al.Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis[J].Coron Artery Dis,2020,31(7):628-635.
7 Agarwal R.Defining end-stage renal disease in clinical trials: a framework for adjudication[J].Nephrol Dial Transplant,2016,31(6):864-7.
8 Rastogi A,Bhatt N,Rossetti S,et al.Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm[J].J Ren Nutr,2021,31(1):21-34.
9 Pasaoglu OT,Senelmis A,Helvaci O,et al.FGF23,alpha-Klotho and vitamin D mediated calcium-phosphate metabolism in haemodialysis patients[J].J Med Biochem,2021,40(2):160-166.
10 Rodríguez M.FGF23:Is It Another Biomarker for Phosphate-Calcium Metabolism?[J].Adv Ther,2020,37(Suppl 2):73-79.
11 Edmonston D,Wolf M.FGF23 at the crossroads of phosphate,iron economy and erythropoiesis[J].Nat Rev Nephrol,2020,16(1):7-19.
12 闫奇奇,郝丽,张森.FGF23与CKD患者钙磷代谢及心血管疾病关系研究进展[J].安徽医科大学学报,2019,54(1):158-162.
13 Memmos E,Papagianni A.New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients[J].Curr Vasc Pharmacol,2021,19(1):55-62.
14 李小媚.列线图个体化预测老年慢性肾衰竭血液透析患者发生心脏瓣膜钙化模型的建立[J].临床肾脏病杂志,2021,21(4):297-301.
15 Hage S,Hage V,El-Khoury N,et al.Musculoskeletal disorders in hemodialysis patients: different disease clustering according to age and dialysis vintage[J].Clin Rheumatol,2020,39(2):533-539.
16 Summerhill VI,Moschetta D,Orekhov AN,et al.Sex-Specific Features of Calcific Aortic Valve Disease[J].Int J Mol Sci,2020,21(16):5620.
17 Li M,Xue W,Li X,et al.Axl is related to inflammation in hemodialysis patients[J].Mol Immunol,2021,133(1):146-153.
18 Coronado MJ,Bruno KA,Blauwet LA,et al.Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis[J].J Am Heart Assoc,2019,8(2):e008968.
19 林胜,王华国.血清sST2、NT-proBNP水平与血液透析患者发生心力衰竭的相关性分析[J].标记免疫分析与临床,2021,28(1):71-75.
20 Matilla L,Ibarrola J,Arrieta V,et al.Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: an in vitro and in vivo study in aortic stenosis[J].Clin Sci (Lond),2019,133(14):1537-1548.
21 Brown RB.Stress,inflammation,depression,and dementia associated with phosphate toxicity[J].Mol Biol Rep,2020,47(12):9921-9929.
